Madrigal Pharmaceuticals Files 8-K
Ticker: MDGL · Form: 8-K · Filed: May 7, 2024 · CIK: 1157601
Sentiment: neutral
Topics: sec-filing, financial-update
TL;DR
Madrigal Pharma filed an 8-K, expect financial updates soon.
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates that Madrigal Pharmaceuticals is providing updates on its financial performance and operational status to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a standard SEC disclosure and does not inherently present new risks.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- SYNTA PHARMACEUTICALS CORP (company) — Former Company Name
- May 7, 2024 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific figures.
When was this 8-K filed?
This 8-K was filed on May 7, 2024.
What is the principal executive office address for Madrigal Pharmaceuticals?
The address is Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania 19428.
What is the company's telephone number?
The company's telephone number is (267) 824-2827.
Has Madrigal Pharmaceuticals changed its name previously?
Yes, the company was formerly known as SYNTA PHARMACEUTICALS CORP, with a name change date of August 15, 2001.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-07 07:06:34
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The Nasdaq
Filing Documents
- d828444d8k.htm (8-K) — 26KB
- d828444dex991.htm (EX-99.1) — 56KB
- g828444dsp05.jpg (GRAPHIC) — 5KB
- 0001193125-24-132559.txt ( ) — 223KB
- mdgl-20240507.xsd (EX-101.SCH) — 3KB
- mdgl-20240507_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240507_pre.xml (EX-101.PRE) — 11KB
- d828444d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release Dated May 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi C. Dier Name: Mardi C. Dier Title: Senior Vice President and Chief Financial Officer Date: May 7, 2024